IMP - IR Newsletter April 2021

I. REPORT ON BUSINESS AND PRODUCTION RESULTS IN APRIL 2021

(Unit: Billion dongs)

Total net revenue and income in April attained 105.2 billion dong, increased over 62% compared to the corresponding month of the previous year due to the fact that social distancing was applied in April 2020, so revenue of the Company is very low. Total net revenue and income accumulated until April 2021 was 406.4 billion dong, making up 26.6% of the annual target and growing by 10.1%.
While profit before tax in the first four months of 2021 achieved 76.2 billion dong, which rose by 23.1% and met 26.3% annual plan. Because net revenue grew by 8.9%, but cost of goods sold only went up by 5.3% together with significant raise in other income (increased 4.6 billion dong); therefore, profit before tax accumulated until the end of April 2021 witnessed a rapid increase.
Selling expenses rose by 12.4% and Imexpharm in the first months of 2021 started to boost customer care and business support activities in both OTC and ETC channel. Thus, expenditures for sales grew and administrative expenses also increased 5.4% year over year.
Despite strengthening operations to stimulate revenues after the pandemic was gradually controlled, the Company still tightly monitors expenses to accomplish the profit target for the whole year as well as tackle the issues induced by the uncertain market when the pandemic has a negative movement tendency in the end of April 2021.

II. IMPSTOCK IN APRIL 2021

In April, there were 5,265,821 IMP stocks being traded. In which, the total volume transacted via order matching was 2,276,200 and 2,989,621 stocks have been dealt via put through the method. The total number of transacted stocks in April of Imexpharm increased more than fourfold compared to April of 2020.
The average number of order matching stocks in April 2021 was 113,810 shares per day. On 02 April, there was the largest number of stocks trading under the order matching method with 1,045,900 shares. On the other hand, prices of IMP at closing rounds in April were not fluctuated in general, the closing price at 01 April was 73,500 whereas the closing price at the last round of the month was 72,600 dong/share. The highest closing price within the month was 74,000 dong, which was recorded on the transaction day of 05 April.

III. REMARKABLE INFORMATION IN APRIL 2021 AND PLANS FOR MAY 2021

In April, Imexpharm has successfully conducted the Annual General Meeting of Shareholders 2021 at Cao Lanh. The contents needing to voted have been passed with a high consensus rate.
Movements of the pandemic are complicated at the end of April; therefore, Imexpharm has been reviewing marketing activities in order to comply with the measures fighting against the pandemic of the Government and reinforce selling activities of the Company.
The Company also closely follow up the circumstance of IMP4 plant to take prompt actions in order to ensure the inspection schedule for this factory.